-
Utilization of angiotensin receptor blockers (ARBs) in Canada
In 2018/19, Health Canada, the US FDA, and other regulatory agencies issued recalls of N-nitrosodimethylamine (NDMA)- and N-nitrosodiethylamine (NDEA)-contaminated angiotensin receptor blockers (ARBs). Despite timely dissemination of these safety communications, little is known about how prescribers and patients responded to the notices.
Q20-02_CDMPatterns of steroid utilization in COVID-19 patients
This population-based study of COVID-19 outpatients in three Canadian provinces, demonstrated that use of systemic corticosteroid therapy as a treatment for COVID-19 was limited during the first year of the pandemic.
Q21-02_CDMNatural coagulopathy and characteristics of its treatment in COVID-19 patients
Recently studies have identified multiple abnormalities of coagulation in many COVID-19 patients. The factors associated with the development of thrombosis in patients with COVID-19 have not been fully evaluated and so the understanding of the determinants of thrombotic events in COVID-19 is important to reducing their risk.
Q20-21_CDM